LENZ Therapeutics, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-1.21 | $-1.02 | +15.7% | Beat |
| Q12026 FY2026 | $-1.10 | $-1.32 | -20.0% | Miss |
| Q42025 FY2025 | $-0.91 | $-1.16 | -27.5% | Miss |
Back to LENZ overview · LENZ holders · LENZ KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.